---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-010790"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T21:58:37.365931+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo reports $257.8M net loss for FY2023; cash runway into Q3 2024

## Summary
- Net loss $257.8M ($1.48/share) on revenue $176.2M (up 58% YoY on Biogen termination).
- Cash $81.0M as of Dec 31, 2023; expects funding into Q3 2024 without additional capital.
- STAC-BBB capsid showed 700-fold higher brain transduction vs AAV9 in NHPs; pain IND Q4 2024.
- Fabry drug aligned with FDA on abbreviated approval pathway; EMA PRIME granted; seeking partner.
- Wind down of French ops (93 roles); 2024 GAAP opex guidance $145–165M.

## SEC filing metadata
- accession: 0001628280-24-010790
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828024010790/0001628280-24-010790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828024010790/sgmo-20240313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-010790
- JSON: https://secwatch.observer/filing/0001628280-24-010790.json
- Plain text: https://secwatch.observer/filing/0001628280-24-010790.txt

## Key facts
- Earnings Releases
  SANGAMO THERAPEUTICS, INC reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 13, 2024, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the year ended December 31, 2023 (the “Press Release”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828024010790/0001628280-24-010790-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.